The rationale behind the treatment is that, because genetic FXI deficiency has been linked with reduced risk of ischemic ...

The factor XIa inhibitor asundexian reduced recurrent ischemic stroke without increasing major or minor bleeding in patients ...

Bayer has linked asundexian to a 26% reduction in stroke in a phase 3 study, setting the bar for Bristol Myers Squibb and ...

Adults hospitalized with an acute respiratory syncytial virus (RSV) infection faced an increased risk of cardiorespiratory events such as heart attack or stroke in the weeks afterward, according to a ...

Sotagliflozin, a dual SGLT1/2 inhibitor, shows benefit specifically for reducing myocardial infarction and stroke risks. Among patients with type 2 diabetes and chronic kidney disease (CKD) at ...

Level of risk peaked in the week after a hospital admission but lingered through 6 months ...

Not all subtypes carry the same long-term cardiovascular risks, South Korean analysis show ...

Some patients with an acute large-vessel ischemic stroke who already show a large-core infarct at early imaging can still benefit from thrombectomy, especially if the procedure successfully restores ...

A secondary analysis of the phase 2 PACIFIC-STROKE trial showed that asundexian is effective for the secondary prevention of stroke in patients with stroke of atherosclerotic origin, but not those ...

THE age you first start smoking has a major effect on your risk of heart disease – more than the number of years you’ve ...

Endovascular therapy for acute ischemic stroke is generally avoided when the infarction is large, but the effect of endovascular therapy with medical care as compared with medical care alone for large ...